Departments of Pediatric Oncology, VU University Medical Center, Amsterdam, the Netherlands.
Mol Cancer Ther. 2013 Feb;12(2):141-50. doi: 10.1158/1535-7163.MCT-12-0735. Epub 2012 Dec 27.
Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric disease. Thus far, no therapeutic agent has proven beneficial in the treatment of this malignancy. Therefore, conventional DNA-damaging radiotherapy remains the standard treatment, providing transient neurologic improvement without improving the probability of overall survival. During radiotherapy, WEE1 kinase controls the G(2) cell-cycle checkpoint, allowing for repair of irradiation (IR)-induced DNA damage. Here, we show that WEE1 kinase is one of the highest overexpressed kinases in primary DIPG tissues compared with matching non-neoplastic brain tissues. Inhibition of WEE1 by MK-1775 treatment of DIPG cells inhibited the IR-induced WEE1-mediated phosphorylation of CDC2, resulting in reduced G(2)-M arrest and decreased cell viability. Finally, we show that MK-1775 enhances the radiation response of E98-Fluc-mCherry DIPG mouse xenografts. Altogether, these results show that inhibition of WEE1 kinase in conjunction with radiotherapy holds potential as a therapeutic approach for the treatment of DIPG.
弥漫性内在脑桥神经胶质瘤(DIPG)是一种致命的儿科疾病。迄今为止,尚无治疗药物被证明对这种恶性肿瘤有效。因此,传统的 DNA 损伤放疗仍然是标准治疗方法,可暂时改善神经功能,但不能提高总生存率。在放疗过程中,WEE1 激酶控制 G2 细胞周期检查点,允许修复照射(IR)诱导的 DNA 损伤。在这里,我们表明与匹配的非肿瘤性脑组织相比,WEE1 激酶是原发性 DIPG 组织中表达最高的激酶之一。用 MK-1775 抑制 WEE1 会抑制 IR 诱导的 WEE1 介导的 CDC2 磷酸化,导致 G2-M 阻滞减少和细胞活力降低。最后,我们表明 MK-1775 增强了 E98-Fluc-mCherry DIPG 小鼠异种移植物的辐射反应。总之,这些结果表明,WEE1 激酶抑制联合放疗具有作为 DIPG 治疗方法的潜力。